Animal model
Ratte
Chang CH et al. 2011
Accelerated healing of tendon injuries
What does NOT follow: Observed in an animal model — not confirmed in humans.
Peptide entry · Healing
BPC-157
Body Protection Compound 157 · Bepecin · PL 14736
Highest evidence
Animal model
Studies recorded
5
Legal status · US
Research onlyScientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope.
Researched for
Tendon and ligament healingGastric mucosal protectionAngiogenesisTissue repair
Official status
US: Research only
Not approved as a medicinal product; FDA restriction on compounding pharmacies.
Overview
What is it?
Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope.
How is it meant to work? →
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of …
What do studies show? →
Animal modelAccelerated healing of tendon injuries
What do users report? →
Faster recovery from sports and tendon injuries (tennis elbow, Achilles tendon, knee ligaments).⚠ anecdotal – not scientific evidence
01
Mechanism of action
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Animal model
Ratte
Sikiric P et al. 2010
Protection of the gastric mucosa
What does NOT follow: Preclinical; cannot be transferred to humans without clinical studies.
In vitro
Zellkultur
Hsieh MJ et al. 2017
Influence on neovascularisation (angiogenesis)
What does NOT follow: In-vitro observation — does not predict an effect in a living organism.
Theoretical
—
Improved wound healing in humans
What does NOT follow: No controlled human studies available.
04
Where studies disagree
Open question
Is BPC-157 sufficiently stable for relevant oral bioavailability in humans?
POSITION A
In-vitro data from the original research group suggest stability in acidic environments.
POSITION B
Independent human pharmacokinetic data are entirely absent; without PK data, oral bioavailability is not established.
CURRENT STATE · Open question. The available data do not support a robust statement on human oral bioavailability.
Open question
Are the reported animal-model effects a generalisable healing phenomenon or model-specific findings?
POSITION A
Broad effect range in the original group's reviews suggests a generalisable mechanism.
POSITION B
Independent replications outside the original research group are rare and inconsistent.
CURRENT STATE · Need for independent replication in larger, controlled samples.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 4 h. Pure pharmacokinetic model — not a dosing recommendation.
Open in PK tool →Start time: t₀ = 0h
Repeat interval: off (single dose)
06
Routes of administration in the literature
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
Most common route in published animal studies.
Oral
Administered orally in some gastrointestinal animal models; pharmacokinetic stability in humans unclear.
Intramuscular
Occasionally described in preclinical studies.
06b
Amounts reported in sources
Which amounts were reported in which source — ordered by context (approval, trial, animal model, secondary literature, community).
06c
Storage & stability
What prescribing information and stability literature report about storing the substance — descriptive, not a mixing or usage guide.
Lyophilized · short-term
2–8 °C, several weeks to months (general peptide stability).
Lyophilized · long-term
−20 °C or colder, longer term.
Reconstituted · storage
When in solution: 2–8 °C, protected from light.
Reconstituted · shelf life
Limited — dissolved peptides are markedly less stable than the dry powder.
What the stability literature describes
- •Peptides are shear-sensitive — vigorous shaking can cause aggregation and loss of activity through foaming and shear; stability literature describes gentle swirling as gentler.
- •Protect from light, moisture and repeated freeze-thaw cycles.
- •There is no approved prescribing information for BPC-157 — these notes rest on general peptide-stability literature, not a product-specific approval.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
There is no approved human use for this substance. What circulates online about amounts and frequency is self-experimentation without a safety net.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Animal model
Animal models
Injection-site reactions (erythema, local irritation)
Animal-model observation. Human frequency unknown — no controlled human trials.
vereinzelt / sporadic
Animal model
No serious adverse events documented in published animal studies
Absence of findings in small animal studies is not evidence of safety. Long-term human data are entirely absent.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Risks from non-pharmaceutical supply sources
Regulatory and scientific sources report substantial variability in purity, identity and sterility of grey-market substances. Contamination and mis-labelled identity are documented.
Sterility and contamination risk in compounding
The FDA cites contamination and identity risks as rationale for compounding restrictions. Specific incidence data for BPC-157 are not available.
09
Regulatory voices
Direct statements from official assessment documents — paraphrased with date and source link.
FDAU.S. Food and Drug Administration
2023-09Compounding-status decision
The FDA has assessed that BPC-157 does not meet the requirements for inclusion on the list of substances permitted for compounding pharmacies. Reasons cited include incomplete characterisation of safety, purity and identity in available sources.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Faster recovery from sports and tendon injuries (tennis elbow, Achilles tendon, knee ligaments).
by far the most common topic in fitness/peptide communities
Not supported by studies: Not supported by controlled human trials. The natural healing course of a tendon/ligament injury already takes weeks — without a control group, subjective improvement cannot be separated from spontaneous healing. Western clinical studies on human tendon healing are absent.
Relief of digestive complaints, reflux and irritable-bowel symptoms.
common extrapolation from the animal models on gastric mucosa
Not supported by studies: The Sikiric animal studies on gastric mucosa are methodologically solid but cover rats/mice with defined lesions — not functional complaints in humans. Concurrent dietary changes are a clear confounder in the reports.
Reports of adverse effects are notably rare relative to how often it is used — most often transient post-injection fatigue and local injection-site reactions.
rarely discussed (notable underreporting)
Not supported by studies: The near-absence of adverse-event reports is NOT a safety endorsement: there is no pharmacovigilance for an unapproved peptide, grey-market purity is unverified (endotoxin risk), and success bias in forums is well documented.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Cofactors
These cofactors relate to the peptide class, not to a specific use. No recommendation, no dosing.
14
Study register
Animal modelAnimal model
Chang CH et al. · 2011
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
SampleMale Sprague-Dawley rats with surgically transected Achilles tendons.
EndpointMechanical load capacity and histological healing markers of the tendon.
MethodDaily intraperitoneal administration in the microgram-per-kilogram range in Sprague-Dawley rats, starting post-operatively over several weeks.
Findings:Treated animals showed improved healing parameters versus control.
Limitations:Animal model, small sample, no long-term follow-up. Not transferable to humans without clinical studies.
Animal modelReview
Sikiric P et al. · 2010
Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157
Findings:Aggregates several animal studies on gastric mucosal protection, ulcer healing and gastrointestinal adaptations.
Limitations:Review by the same research group — possible selection bias. No human data.
In vitroIn vitro
Hsieh MJ et al. · 2017
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Findings:BPC-157 modulated VEGF signalling and endothelial migration patterns in cell culture.
Limitations:In-vitro finding; says nothing about in-vivo efficacy or clinical relevance.
PreclinicalOther
U.S. Food and Drug Administration · 2023
FDA-Bekanntmachung zu Compounding-Beschränkungen für BPC-157
Findings:Rationale includes lack of characterised safety, purity and identity in available sources.
PreclinicalReview
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM · 2025
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Findings:Confirms the large gap between how widely it is used and the robust human evidence available.
Limitations:Narrative (not systematic) review; summarises predominantly preclinical work.
15
Sources & method
Reviewed by
Dr. [Placeholder]
Last reviewed
2026-05-21
Get new studies on BPC-157
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy